In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.
Age range
6 Months – 24 Months
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Participants With a Change in Cholinesterase Level at 1 Hour (Day 0).
Timeframe: Change from Baseline to 1 hour
Participants With a Change in Cholinesterase Level at 24 Hrs (1 Day).
Timeframe: Change from baseline to 24 hrs (1 day)
Participants With the Clinical Evidence of Cholinesterase Inhibition
Timeframe: at Baseline
Participants With the Clinical Evidence of Cholinesterase Inhibition
Timeframe: at 1 hr (Day 0)
Participants With the Clinical Evidence of Cholinesterase Inhibition
Timeframe: at 24 hrs (Day 1)
Participants Clinically Cured of Head Lice 14 Days After Last Treatment
Timeframe: Day 7±1 and Day 14 or Day 21